Paper23328666
The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.
Miekus K and 5 others. Cell Death Dis, 2013. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation. Papers, record 23328666. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23328666
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.
- PubMed
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Proto-Oncogene Proteins c-met | Major topic |
| Animals | |
| Bone Marrow Neoplasms | |
| Cell Differentiation | |
| Cell Line, Tumor | |
| Cell Movement | |
| Chemokine CXCL12 | |
| Down-Regulation | |
| Hepatocyte Growth Factor | |
| Humans | |
| Mice | |
| Mice, Inbred NOD | |
| Mice, SCID | |
| Mitogen-Activated Protein Kinase Kinases | |
| MyoD Protein | |
| Phosphorylation | |
| Proto-Oncogene Proteins c-akt | |
| RNA Interference | |
| RNA, Small Interfering | |
| Receptors, CXCR4 | |
| Rhabdomyosarcoma | |
| Soft Tissue Neoplasms | |
| Transplantation, Heterologous |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19318576 | The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. | Cancer Res | 2009 | https://conductscience.org/library/papers/19318576 | PubMed |
| 2 | 22027690 | Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. | Mol Cancer Ther | 2012 | https://conductscience.org/library/papers/22027690 | PubMed |
| 3 | 12239174 | CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. | Blood | 2002 | https://conductscience.org/library/papers/12239174 | PubMed |
| 4 | 18451162 | Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling. | Cancer Res | 2008 | https://conductscience.org/library/papers/18451162 | PubMed |
| 5 | 10498887 | Rhabdomyosarcoma--working out the pathways. | Oncogene | 1999 | https://conductscience.org/library/papers/10498887 | PubMed |
| 6 | 12684423 | c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/12684423 | PubMed |
| 7 | 15705897 | Silencing of CXCR4 blocks breast cancer metastasis. | Cancer Res | 2005 | https://conductscience.org/library/papers/15705897 | PubMed |
| 8 | 8187070 | Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. | Cancer Res | 1994 | https://conductscience.org/library/papers/8187070 | PubMed |
| 9 | 21551255 | Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21551255 | PubMed |
| 10 | 20068066 | Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. | Mol Cancer Res | 2010 | https://conductscience.org/library/papers/20068066 | PubMed |
| 11 | 18175071 | The Met tyrosine kinase receptor in development and cancer. | Cancer Metastasis Rev | 2008 | https://conductscience.org/library/papers/18175071 | PubMed |
| 12 | 17981628 | The biological role of HGF-MET axis in tumor growth and development of metastasis. | Front Biosci | 2008 | https://conductscience.org/library/papers/17981628 | PubMed |
| 13 | 3689591 | Myoglobin, desmin and vimentin in ultrastructurally proven rhabdomyomas and rhabdomyosarcomas. An immunohistochemical study utilizing a series of monoclonal and polyclonal antibodies. | Appl Pathol | 1987 | https://conductscience.org/library/papers/3689591 | PubMed |
| 14 | 21926191 | Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. | Mol Cancer Ther | 2011 | https://conductscience.org/library/papers/21926191 | PubMed |
| 15 | 15735036 | Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Cancer Res | 2005 | https://conductscience.org/library/papers/15735036 | PubMed |
| 16 | 8789435 | In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. | Hum Mol Genet | 1996 | https://conductscience.org/library/papers/8789435 | PubMed |
| 17 | 2558065 | Expression of desmin and myoglobin in rhabdomyosarcomas and in developing skeletal muscle. | Histopathology | 1989 | https://conductscience.org/library/papers/2558065 | PubMed |
| 18 | 7665696 | Desmin expression in rhabdomyosarcoma: influence of the desmin clone and immunohistochemical method. | J Clin Pathol | 1995 | https://conductscience.org/library/papers/7665696 | PubMed |
| 19 | 17235634 | Detection of cancer cells disseminated in bone marrow using real-time quantitative RT-PCR of CEA, CK19, and CK20 mRNA in patients with gastric cancer. | Gastric Cancer | 2006 | https://conductscience.org/library/papers/17235634 | PubMed |
| 20 | 15064724 | The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. | Oncogene | 2004 | https://conductscience.org/library/papers/15064724 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41507126 | The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41507126 | PubMed |
| 40508013 | Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40508013 | PubMed |
| 39913888 | Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. | JCO Precis Oncol | 2025 | https://conductscience.org/library/papers/39913888 | PubMed |
| 38474036 | Transforming Growth Factor Beta and Alveolar Rhabdomyosarcoma: A Challenge of Tumor Differentiation and Chemotherapy Response. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38474036 | PubMed |
| 38076999 | Fusion-negative rhabdomyosarcoma orthotopic tongue xenografts for study of invasion, intravasation and metastasis in live animals. | bioRxiv | 2023 | https://conductscience.org/library/papers/38076999 | PubMed |
| 36034555 | The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents. | Front Pediatr | 2022 | https://conductscience.org/library/papers/36034555 | PubMed |
| 35574376 | MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression. | Front Oncol | 2022 | https://conductscience.org/library/papers/35574376 | PubMed |
| 35158790 | NanoString Digital Molecular Profiling of Protein and microRNA in Rhabdomyosarcoma. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35158790 | PubMed |
| 34440639 | Progression and Differentiation of Alveolar Rhabdomyosarcoma Is Regulated by PAX7 Transcription Factor-Significance of Tumor Subclones. | Cells | 2021 | https://conductscience.org/library/papers/34440639 | PubMed |
| 32664538 | SNAIL Promotes Metastatic Behavior of Rhabdomyosarcoma by Increasing EZRIN and AKT Expression and Regulating MicroRNA Networks. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32664538 | PubMed |
| 31949799 | c-MET expression potentially contributes to the poor prognosis of rhabdomyosarcoma. | Int J Clin Exp Pathol | 2018 | https://conductscience.org/library/papers/31949799 | PubMed |
| 30909397 | C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas. | Cells | 2019 | https://conductscience.org/library/papers/30909397 | PubMed |
| 30617281 | Rhabdomyosarcoma. | Nat Rev Dis Primers | 2019 | https://conductscience.org/library/papers/30617281 | PubMed |
| 30373318 | Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma. | Molecules | 2018 | https://conductscience.org/library/papers/30373318 | PubMed |
| 29445192 | SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/29445192 | PubMed |
| 27851822 | Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion. | PLoS One | 2016 | https://conductscience.org/library/papers/27851822 | PubMed |
| 27324022 | Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma. | Cancer Chemother Pharmacol | 2016 | https://conductscience.org/library/papers/27324022 | PubMed |
| 26900544 | Microfabricated Systems and Assays for Studying the Cytoskeletal Organization, Micromechanics, and Motility Patterns of Cancerous Cells. | Adv Mater Interfaces | 2014 | https://conductscience.org/library/papers/26900544 | PubMed |
| 26384300 | Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression. | Oncotarget | 2015 | https://conductscience.org/library/papers/26384300 | PubMed |
| 26162688 | Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors. | Mol Cancer Ther | 2015 | https://conductscience.org/library/papers/26162688 | PubMed |
Genes21
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23328666
GET https://conductscience.org/api/papers/v1/23328666/references?page=2